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ABSTRACT OF THESIS 
 
 
The Prevalence of Temporomandibular Disorders in Fibromyalgia Patients   
Compared to That of Failed Back Syndrome Patients: A Blinded Prospective 
Study. 
  
 
The purpose of this study was to determine the prevalence of 
temporomandibular disorders (TMD) in fibromyalgia (FM) patients compared to 
failed back syndrome (FBS) patients. In addition, the FM and FBS patients were 
assessed and compared with regard to their psychosocial dysfunction. The study 
included 51 adult patients (FM = 32, FBS = 19) recruited from a physical 
medicine and rehabilitation clinic and a FM workshop. Questionnaires included 
an orofacial pain questionnaire and a battery of psychological questionnaires that 
included the Symptom Check List-90-Revised, the Pittsburgh Sleep Quality 
Index, the Multi-dimensional Pain Inventory, the Post-traumatic Stress Disorder 
Checklist-Civilian Version, and Multidimensional Fatigue Symptoms Inventory-
short form. Each patient underwent a clinical examination by a dentist who was 
blind to the diagnostic category and if applicable was diagnosed with TMD based 
on the Research Diagnostic Criteria for TMD. Fifty three percent of the FM 
patients reported having face pain compared to 11% of the FBS patients 
(P=0.002). Of those FM patients who reported face pain, 71% fulfilled the criteria 
for TMD. The psychometric data revealed that the FM patients had higher scores 
for somatization (P=0.02) and obsessive-compulsive (P=0.009) subscales 
compared to the FBS patients. The mean score of medication used to sleep was 
higher among the FM patients compared to FBS patients (P=0.002). Eighty 
seven percent of the FM patients reported a stressful event (P=0.036). Of those 
FM patients who reported a stressful event 42.3% were deemed post-traumatic 
stress disorder positive. FM patient also had higher scores for general fatigue 
(P<0.0001), emotional fatigue (P=0.008), physical fatigue (P<0.0001) and mental 
fatigue (P<0.0001) as compared to FBS patients. The high prevalence of TMD 
and psychosocial dysfunction among FM patients suggests a dysfunctional 
hypothalamic-pituitary-adrenal axis and dysregulated autonomic nervous system. 
 
 
KEYWORDS: Prevalence, temporomandibular disorders, fibromyalgia, failed 
back syndrome and psychosocial dysfunction.  
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Chapter 1. Introduction 
 
Fibromyalgia (FM) is defined as a syndrome of widespread pain and 
stiffness of the locomotor system. Symptoms last at least 3 months with the 
presence of palpable tenderness at 11 or more of 18 established areas involving 
all four body quadrants. This definition is based on findings from a study 
performed by the Multicenter Criteria Committee to define FM and was later 
adopted by the American Academy of Rheumatology (ACR) 1. A more detailed 
explanation of the ACR criteria for FM is illustrated in Figure 1 and Table 1. In 
addition, the Multicenter Criteria Committee highlighted symptoms commonly 
associated with FM such as sleep disturbances, fatigue, paresthesias, anxiety, 
headache and irritable bowel syndrome (IBS) 1. FM is estimated to affect 2% of 
the general population, with a large female preponderance. The syndrome 
increases in prevalence with age 2.  
FM may be classified as primary or secondary, depending on the nature of 
its onset 3. The primary form occurs in adults without association to a known 
                                               2
illness, whereas secondary FM is based on preexisting underlying medical 
disorders such as rheumatoid arthritis, infection, stress, or trauma inducing the 
condition 4 5.  In spite of the above mentioned classification, the exact etiology of 
FM remains elusive and is further complicated by comorbid conditions. These 
comorbidities include that of other “functional somatic syndromes” such as 
chronic fatigue syndrome (CFS), irritable bowel syndrome (IBS), 
temporomandibular disorders (TMD), multiple chemical sensitivities, and tension-
type headache, all of which, including FM, have a degree of overlap in core 
symptoms 6 7.   
Temporomandibular disorders (TMD) is a collective term embracing a 
number of clinical problems that involve the masticatory musculature, the 
temporomandibular joints and associated structures 8. It includes a subset of 
musculoskeletal diagnoses which typically involve the temporomandibular joint 
(TMJ) and/or the muscles of mastication. Common TMJ diagnoses include 
degenerative joint disorders like osteoarthritis, arthralgia or disk displacements 
and are associated with preauricular pain, limited functional jaw movements, jaw 
clicking and/or locking. Muscle disorders include myofascial pain, typically 
presenting as myalgia with local trigger points in muscle bands that can refer 
pain to a remote site. Limited range of jaw movement secondary to reports of 
muscle fatigue is also commonly observed 9 8 10 11.      
In spite of large percentages of the general population exhibiting signs and 
symptoms of TMD 12, the need for treatment is estimated to range between 3.6-
7% 13 14 15 16 9 17 18. This highlights the fact that TMD cases are cyclic in nature, 
                                               3
often self-limiting and mild, and rarely progress to a severe disabling chronic 
state 19 20 9 21.   
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Table 1.     The American College of Rheumatology 1990 Criteria for the 
Classification of FM * 1 
 
1.      History of widespread pain 
 
Definition. Pain is considered widespread when all of the following are 
present: pain in the left side of the body, pain in the right side of the 
body, pain above the waist, and pain below the waist. In addition, axial 
skeletal pain (cervical spine or anterior chest or thoracic spine or low 
back) must be present. In this definition, shoulder and buttock pain is 
considered as pain for each involved side. “Low back” pain is 
considered lower segment pain. 
 
2.       Pain in 11 of 18 tender point sites on digital palpitation. 
 
Definition. Pain, on digital palpitation, must be present in at least 11 of 
the following 18 tender point sites: 
Occiput: bilateral at the suboccipital muscle insertions, 
Low cervical: bilateral, at the anterior aspects of the intertransverse 
spaces at C5-C7. 
Trapezius: bilateral, at the midpoint of the upper border. 
Supraspinatus: bilateral, at origins, above the scapula spine near the 
medial border. 
Second rib: bilateral, at the second costochondral junctions, just lateral 
to the junctions on the upper surfaces. 
Lateral epicondyle: bilateral, 2 cm distal to the epicondyles. 
Gluteal: bilateral, in upper outer quadrants of buttocks in anterior fold 
of muscle. 
Greater trochanter: bilateral, posterior to the trochanteric prominence. 
Knee: bilateral, at the medial fat pad proximal to the joint line. 
 
      Digital palpitation should be performed with an approximate force of 4 kg. 
 For a tender point to be considered “positive” the subject must state that    
 the palpation was painful. “Tender” is not to be considered “painful.”  
______________________________________________________________ 
 
*For classification purposes, patients will be said to have fibromyalgia if both 
criteria are satisfied. Widespread pain must have been present for at least 3 
months. The presence of a second clinical disorder does not exclude the 
diagnosis of fibromyalgia.  
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Figure 1: Locations of FM tender points on the human body as defined by the 
American College of Rheumatology 1990 criteria for the classification of FM 1 
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Table 2. Prevalence of frequently observed symptoms and signs in FM (% of 
patients) 5 
 
Widespread pain with tender points      100 
Generalized weakness, myalgias, arthralgias       80 
Nonrestorative sleep          80 
Fatigue            70 
Stiffness            60 
Tension headache                               53 
Dysmenorrhea           40 
Irritable colon, functional bowel disease        40 
Subjective numbness, swelling, tingling        35 
Livedo reticularis or skin hyperaemia        30 
Complaints of fever                     20 
Complaints of swollen glands         20 
Complaints of dry eyes          20 
Subjective significant cognitive dysfunction       20 
Significant psychopathology                                                                   5-20 
Nocturnal myoclonus, restless leg syndrome       15 
Female urethral syndrome                    12 
Vulvodynia or vaginismus          10 
Concomitant reflex sympathetic dystrophy          5 
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Chapter 2. Purpose of the Study 
 
The aim of the present study is to determine the presence of TMDs in FM 
patients compared to failed back syndrome (FBS) patients. It is hypothesized that 
FM patients will exhibit greater signs and symptoms of TMDs when compared to 
FBS patients. It is also hypothesized that both FM and FBS patients will exhibit 
significant psychosocial dysfunction.  
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Chapter 3. Review of the Literature 
  
 
3.1. Temporomandibular Disorders  
Temporomandibular Disorders is a subclassification of musculoskeletal 
disorders that can cause pain in the orofacial region 12. In the past, TMD was 
considered a syndrome representing one disorder commonly referred to as 
“TMJ,” but it is now considered a collective term representing various related 
disorders of the masticatory system 8 12 22. Pain originating from the masticatory 
muscles or TMJs is the most common complaint and is frequently accompanied 
by limited and/or asymmetric mandibular movement, and joint clicking and/or 
crepitation 8.           
To date, there is no universal known cause of TMD, although numerous 
associative factors have been identified. It is likely that there is no one etiology 
for TMD. Certain factors may affect the dynamic balance of the masticatory 
system and increase the risk for dysfunction and pathology, rather than promote 
ongoing adaptive physiologic health and function 23 8.   
 
3.1.1 Prevalence of Temporomandibular Disorders 
Prior to addressing the prevalence of TMD, it is important to recognize that 
until recently there were essentially no evidence-based guidelines for the 
diagnosis and classification of TMD. The available cross-sectional 
epidemiological studies were heterogeneous in TMD terminology, data collection 
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and interpretation of the variables studied 8.  Poor correlation between signs 
(abnormal jaw movement, joint sounds, pain upon palpation) and symptoms 
(face pain, joint pain) of TMD also led to questionable interpretation of their 
clinical significance 17. The standardization of TMD diagnoses was addressed by 
the Research Diagnostic Criteria (RDC) committee with aims to improve the poor 
quality of past epidemiology studies in TMD 24.  
Okeson summarized the prevalence of commonly reported symptoms and 
examined signs of TMDs based on 17 studies 12. It was reported that signs and 
symptoms of TMD are common in the general population. Report of at least one 
TMD symptom ranged from 14% to 74%, and clinical findings of at least one 
TMD sign ranged from 15% to 88% 25 26 27 28 29 30 31 32  33 34 35 36 37 38 39 40 41. 
Careful interpretation of these studies is pertinent as clinical signs are often 
unknown to the patient and their relevance should be scrutinized 42. As 
previously mentioned, in spite of the high prevalence of TMD signs and 
symptoms, various studies showed that the need for treatment ranged only 
between 3.6-7% 13 14 15 16 9 17 18. Although TMD symptoms requiring treatment 
are uncommon complaints, TMD signs were found to increase with age in 
children and young adults. In fact, TMD symptoms are more frequently reported 
in patients between 20-40 years but not often in those who are older than 60 
years 42 43 21 44 45 46. This highlights the cyclic and rarely progressive nature of 
TMD signs and symptoms 19 20 9 21. It is also worth mentioning that in spite of the 
low overall prevalence of TMD 47, the societal cost as measured by yearly work 
days lost is significant. It is reported that 17.8 million work days are lost each 
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year in the United States due to disabling TMD for every 100 million full-time 
working adults 16.    
 
3.1.2 Etiology and Pathophysiology of Temporomandibular Disorders 
The etiology of TMD remains elusive which is partly due to its unknown 
pathophysiology. The pathophysiology of TMD is multifactorial and varies 
depending on the subclassification of TMD. For example, the pathophysiology of 
masticatory myofascial pain is likely different than capsulitis of the TMJ 8.    
Currently there are certain factors that are recognized as associated with 
TMD but not necessarily causal. These factors may predispose, initiate and/or 
perpetuate TMD under different circumstances 48 49 50. They may affect the 
dynamic equilibrium of the masticatory system 23 shifting it from an adaptive 
physiologically healthy system to that of dysfunction and pathology. Although 
speculative, the imbalance towards dysfunction and pathology is potentially 
influenced by the psychological status of TMD patients 51. The psychological 
status of TMD patients will be discussed more extensively in the following 
section.   
The etiology of TMDs may be due to trauma, anatomic considerations, 
pathophysiology and psychological issues. Trauma may be direct such as a blow 
to the mandible, indirect such as acceleration-deceleration injury or microtrauma 
such as clenching and grinding of teeth 8. Anatomic factors that are associated 
with and may possibly represent TMD etiology may be divided into skeletal and 
occlusal relationships. Skeletal factors include articular eminence steepness, 
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skeletal malformations and inter-arch and intra-arch discrepancies. Occlusal 
factors include discrepancies between retruded contact and intercuspal position, 
loss of molar support, extensive overbite, overjet and crossbite. The roles of 
anatomic factors are currently believed to be less significantly associated with 
TMD than previously thought and this will be explained under the TMD and 
psychological issues section 8.  
As previously mentioned, the pathophysiology of TMD is not currently 
known but the speculations are numerous and varied. Factors may be systemic 
such as degenerative, endocrine, infectious and rheumatologic. 
Temporomandibular disorders secondary to pathophysiologic factors may include 
FM as a systemic causative factor. On the other hand, local pathophysiologic 
factors include synovial fluid viscosity, intracapsular pressure, and female 
hormone levels 8. 
As an illustration of the role of female hormones on TMD pathophysiology, 
an increase in TMD pain was noted in women during lowest estrogen levels or 
rapid estrogen change 52. It has been suggested that exogenous hormones in the 
form of oral contraceptives may reduce fluctuations in estrogen during the 
menstrual cycle. Therefore, exogenous hormones may be beneficial in chronic 
TMD patients as they counteract estrogen depletion in late luteal and menses 
phases of the menstrual cycles and avoid rapid estrogen changes experienced 
during ovulation 53.  
Psychological factors may affect the ability of TMD patients to cope with 
difficult life situations. The relationship between psychological distress and 
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physiological consequences particularly has been established among TMD 
patients with Post-traumatic Stress Disorder (PTSD) 54 55. It is to be determined if 
psychological factors cause TMD or are the result of TMD or both. The following 
section will discuss the relationship between TMD and psychological factors 
more extensively 8.   
In summary, regarding the pathophysiology and etiology of TMD, much 
controversy remains. Many factors have been identified that may predispose, 
initiate and/or perpetuate TMD. Further studies are needed to determine the 
significance of these factors. It is likely that the relationship between 
psychological distress and its physiological consequences will determine the 
ability of the system to adapt versus to be prone to dysfunction and pathology.  
 
3.1.3. Temporomandibular Disorders and Psychosocial Issues  
The RDC for TMD involve two axes. Axis I is comprised of the physical 
conditions of masticatory myofascial pain (MM) and/or TMJ pain. Axis II is 
comprised of the psychological conditions and its effects in producing and/or 
influencing the pain experience 24.  
The link between TMD and psychological issues has been previously 
established 56 57 58. In contrast to healthy controls, TMD patients have higher 
levels of depression and anxiety 59 51 60 61 62 63. In addition, MM pain patients 
frequently have more psychological issues compared to TMJ pain patients, with 
elevated levels of depression, pain disability, and increased exposure to major 
life stressors 64 65 66 55 67.  
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To further understand the link between TMD and psychological issues, 
McEwen in 1998 proposed the allostatic load theory. The theory suggests long-
term overactivity of the allostatic systems which are comprised of the autonomic 
nervous, cardiovascular, metabolic, immune systems and hypothalamic-pituitary-
adrenal (HPA) axis is detrimental in chronic pain 68. It has been established that 
the activity of the sympathetic portion of the autonomic nervous system is 
increased by emotional stress. This is characterized by an increase in the arterial 
blood pressure, blood flow to muscles, muscle activity, and mental activity, 
commonly referred to as the “fight or flight” response 69. Under acute stressful 
conditions, this increased autonomic activity is favorable. However, persistent 
chronic stressors, including major life events, may have long term consequences 
on the person’s physical health 68. It has been established that chronic emotional 
stress can contribute to pain and can increase pain severity as a result of 
overactive central nervous, autonomic and musculoskeletal systems 70. Indeed, 
chronic TMD patients demonstrate increased cardiovascular activity and altered 
breathing rate compared to normal controls 63.  
Thayer and Friedmann (2002) 71 described a self-organizing dynamic 
system that governs the behavior of living systems. The ability of the system to 
function efficiently when challenged by environmental demands is often 
secondary to efficient inhibitory processes. The authors also suggested that the 
process of sensitization is not always determined by overall hyperactivity. It may 
be the result of a loss of inhibitory neural processes leading to maladaptive 
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activation of fewer brain pathways. Therefore, loss of inhibitory control may be 
critical for efficient adaptability.    
It is believed that the dysregulation of the HPA-axis may predispose 
individuals for the development of chronic pain 72, though neuroendocrinologic 
investigations involving TMD have reported inconsistent findings. Jones et al 
(1997) found that TMD patients had increased or typical levels of cortisol 
released in response to stress compared to healthy controls 73. On the contrary, 
Venable (2003) reported hypocortisolism among TMD patients consistent with 
findings of other stress-related disorders such as FM and chronic fatigue 
syndrome 74. However, Korszun et al (2002) in a study involving 15 female TMD 
patients revealed hypercortisolism compared to a control group 75. It seems 
logical that cortisol levels may fluctuate with transient stressors, as demonstrated 
by actual stress of venipuncture or anticipatory anxiety associated with 
venipuncture 76. In summary, chronic pain disorders, including TMD, are 
potentially related to dysregulation of the HPA-axis. 
As previously mentioned, the overall data 59 51 60 61 62 63 64 65 66 55 67 
suggest TMD patients exhibit significant psychological dysfunction. A model 
integrating the physical signs and symptoms and psychological distress in TMD 
has been detailed 51. Carlson et al (1998) studied and integrated the 
psychological and physiological parameters of muscle pain TMD patients.  This 
study involved monitoring emotional and physiological responses (heart rate, 
blood pressure, respiration, skin temperature, and muscle activity) of muscle pain 
patients and age, sex and weight matched normal controls. Patients and controls 
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completed a series of questionnaires prior to a laboratory evaluation consisting of 
a psychosocial stressor and pressure pain stimulation at multiple body sites. The 
muscle pain patients reported greater fatigue, disturbed sleep, depression, 
anxiety, menstrual symptoms and less self-deception than normal controls. In 
addition, muscle pain patients had lower end tidal carbon dioxide levels and 
lower diastolic blood pressures at rest than normal controls. The authors 
suggested a central nervous system link between the physiology and psychology 
in muscle pain TMD patients that affected their ability to recover physiologically 
51. Other studies have reported data from TMD patients that implicated altered 
sensory pain experiences as a result of dysfunction in the modulatory controls of 
the central nervous system 77 78. This is further data concerning the role of a 
dysfunctional central nervous system contributing to the pathophysiology of TMD. 
 
3.1.4. Temporomandibular Disorders and Sleep Disturbance  
There is a strong relationship between sleep and chronic pain 79 80 81 82. 
However, it is yet to be established whether chronic pains produce a sleep 
disturbance or a sleep disturbance is significant in the instigation of chronic 
pains. It has been suggested that progression of an acute muscle pain to a 
chronic pain condition may be perpetuated by sleep disturbances 83. In fact 
stage-four deprivation led to musculoskeletal symptoms such as muscle 
tenderness and stiffness in healthy patients, but such symptoms were not 
observed following disruption of the rapid eye-movement (REM) sleep. This 
suggests that poor sleep quality of the deeper sleep stages may be linked to 
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chronic pain conditions. The musculoskeletal symptoms are likely a consequence 
of the failure to restore the metabolic functions of the body systems that occur in 
deeper sleep stages 84. Sleep disturbances are common complaints of TMD 
patients; 85 86 87 with higher preponderance among muscle pain patients 
compared to TMJ pain patients 66 88.  
 
3.1.5. Summary 
From the aforementioned review it is apparent that a more precise 
prevalence of TMD is yet to be determined. This is due to previous studies 
having heterogeneous TMD terminology, varied data collection strategies and 
differences in interpretation of the variables. Likewise, TMD pathophysiology and 
etiology is yet to be determined, although numerous associated factors have 
been identified. The relationship between TMD and psychosocial issues is 
established but its impact also remains to be determined. It has been proposed 
that dysregulation of the HPA-axis and autonomic nervous system as well as loss 
of inhibitory neural modulation are associated with TMD as well as other chronic 
pain conditions. 
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3.2. Fibromyalgia 
Sir Edward Gowers coined the term fibrositis (old term for FM) to further 
classify lumbago in the early 20th century 89. However, Smythe and Moldofsky 
first recognized the consistent palpable soft tissue tender points associated with 
widespread pain of fibrositis 90. Since that time, there has been much debate on 
the credibility of persons presenting with signs and symptoms of a generalized 
musculoskeletal system pain consistent with FM. The financial burden these 
patients pose on governments and insurance companies is significant 91 92 93. 
This motivated, in part, the development of the FM classification criteria in 1990 
by the ACR, which are now used throughout the world for investigating this 
enigmatic condition 1. In spite of ongoing criticism of the subjective nature of FM 
complaints, the classification is moderately sensitive (88.4%) and specific 
(81.1%) and hence useful for distinguishing FM from other chronic pain 
syndromes 1. Physical findings of FM are based on palpation pressure of 4 
kilograms resulting in pain in at least 11 of the potential 18 tender points 
including skeletal muscles, ligaments and bursae.  Pain upon palpation felt in 
these tender points is thought to represent allodynia. For details of the 
classification, see Table 1 and Figure 1. 
The prevalence of FM in the adult population is estimated to be 2% (0.5% 
males and 1.5% females) with the highest prevalence being in women between 
the age of 50-60 years 1 94. It has been reported that 6-10% of patients in a 
physician’s waiting room meet the classification criteria for FM 95. FM patients 
typically describe their pain as persistent, diffuse, deep, aching, throbbing, and/or 
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stabbing pain associated with dysesthesia. Apart from the obvious reporting of 
pain and associated typical tender points, FM patients commonly present with 
symptoms of anxiety, depression, sleep disturbances, dizziness, morning 
stiffness, physical fatigue, IBS and interstitial cystitis 96 (Table 2). The comorbidity 
of FM with other conditions such as chronic fatigue syndrome, IBS, TMD, chronic 
headaches and interstitial cystitis may be related to a reduction in pain threshold 
and tolerance mediated by central nervous system mechanisms. In addition, 
these conditions are marked by a heightened sensitivity to both physical and 
psychological stress 96 97 7 98 99.  
 
3.2.1 Etiology and Pathophysiology of Fibromyalgia 
The etiology of FM is not known. An autosomal dominant inheritance for 
FM has been reported but no gene abnormalities have been identified 100. 
Histologic and electromicroscopic studies have failed to discover skeletal muscle 
abnormalities 101.  
The preponderance of females with FM may provide some insight to the 
pathophysiology of FM. Epidemiology studies have revealed a lower pain 
threshold for females compared to males in healthy populations 94 102. This may 
be explained by the lower levels of 5-hydroxytryptophan (5-HT) synthesis and 
metabolism. A radiology study involving CNS positron emission tomography 
revealed lower conversion rate of methylated analog of 5-HT to 5-hydroxyindole 
acetic acid among healthy adult females. These data suggest a gender-related 
difference in antinociceptive activity. Interestingly, in spite of a large female 
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preponderance for FM, a relationship between FM and circulatory sex hormones 
has not been established 103 104.   
FM patients may present with neuroendocrine dysfunction involving the 
HPA-axis, the sympatho-adrenal system, the hypothalamus-pituitary-thyroid axis 
or the hypothalamic-pituitary-growth hormone axis 105 106 107 108. It has been 
suggested that abnormalities in serotonin and norepinephrine availability in the 
CNS may explain the neuroendocrine dysfunction 109. Studies have also revealed 
lower adenosine triphosphate (ATP) levels in the red blood cells of FM patients 
110 111 and this may explain low levels of platelet serotonin since ATP is required 
for serotonin platelet binding and uptake.  
One third of FM patients had a drop in blood pressure, some with 
episodes of syncope, when undergoing tilt-table testing suggesting an autonomic 
nervous system dysfunction 112. Studies on diurnal heart rate variability among 
FM patients revealed sustained sympathetic tone at night 113. A sustained 
dysfunctional sympathetic tone may be due to a loss of inhibitory neural 
pathways leading to maladaption 114 71. These findings suggest that like TMDs, 
FM patients experience a loss of inhibitory control.          
Serum studies of FM show abnormal biochemical levels of tryptophan, 
serotonin, substance P 96, and growth hormone. Dysregulation of diurnal cortisol 
production has also been documented 106. These neurochemical abnormalities 
may suggest a facilitation or failure in inhibition of nociception leading to central 
sensitization and increased pain perception. They may affect the dynamic 
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equilibrium of the system that shifts it from an adaptive physiologically healthy 
system to that of dysfunction and pathology 114 71. 
Taken together, the pathophysiology and etiology of FM remain unknown. 
However, much progress has been made in understanding factors associated 
with the syndrome. The old school of thought whereby FM patients were once 
considered depressed somatizers is now considered unlikely. Abnormal CNS 
neurochemicals such low 5-HT and high substance P are more likely 
explanations of the pain amplification represented in FM.     
 
3.2.2. Fibromyalgia and Psychosocial Issues 
As previously discussed, the pathophysiology of FM remains an enigma. It 
has been reported that FM may merely represent somatic manifestations of an 
affective disorder, further supported by the lack of an objective measure of this 
syndrome 115. Interestingly, rheumatoid arthritis (RA) was also once considered 
an affective disorder 116 117. Studies involving RA and FM reported FM patients 
as having higher scores compared to RA patients for hypochondriasis, hysteria, 
psychotic behavior, paranoia, and schizophrenia as measured by the Minnesota 
Multiphasic Personality Inventory (MMPI) 118. Similarly, another study reported 
that FM patients had a 70% lifetime rate of major affective disorder compared to 
13% among RA patients. Of the FM patients with major depression, 64% 
reported the onset of affective symptoms occurring at least one year after the 
diagnosis of FM. This suggests that FM patients are depressed as a result of 
their somatic symptoms, rather than that major depression resulted in somatic 
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manifestations. However, this study also revealed that 10% of 1st degree 
relatives of FM patients were depressed compared to only 3% of the RA patients 
115.  
It is has been established by various studies that depression does exist 
among FM patients but whether it is significantly more prevalent among FM 
patients compared to other chronic pain patients remains controversial. Some 
studies suggest that FM patients are more depressed than RA patients 4 119 
whereas others suggest that although depression may exist, there is no 
difference in the prevalence of depression among the two groups of patients 120 
121 122 123.  It is likely that the presence of depression and anxiety may amplify the 
pain and fatigue experienced by FM patients 124. The reverse outcome is likely as 
well, whereby affective symptoms may be the result of chronic pain, fatigue, 
sleep disturbances and a reduced quality of life.   
 
3.2.3 Fibromyalgia and Sleep Disturbances 
 FM patients frequently complain of disturbed, non-refreshing sleep 96 1. It 
has been suggested that increased pain in FM patients may contribute to sleep 
disturbances and sleep disturbances may result in increased pain in FM patients 
79. Polysomnographic studies have reported intrusion of alpha frequency 
electroencephalogram during non-rapid eye movement sleep among FM patients 
125 126. Interestingly, FM-like symptoms may be associated with sleep 
disturbances in healthy patients 127. Whether sleep disturbances have a role in 
the pathophysiology of FM is to be determined. 
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3.2.4 Summary 
From the above mentioned review, it is apparent that FM remains a 
perplexing condition. Further studies on its prevalence, etiology and 
pathophysiology are pertinent as it may improve existing treatment strategies and 
motivate research for newer treatments.  The key to deciphering this difficult 
condition probably lies in understanding the role of autonomic nervous system 
dysfunction and loss of inhibitory neural modulation.   
 
3.3. Temporomandibular Disorders and Fibromyalgia 
Numerous studies in the past have suggested relationships between FM 
and TMD 128 129 130 131 132 133 134. The conclusions drawn from these studies seem 
logical based on the definition of FM as a form of non-articular rheumatism 
characterized by widespread muscle pain, tenderness to palpation and stiffness 
of the locomotor system 94. It seems reasonable that FM may encompass TMD, 
which is a collective term embracing a number of clinical problems that involve 
the masticatory musculature, the TMJ and associated structures 8. 
Hedenberg-Magnusson et al (1999) suggested that FM is a cause of TMD. 
The authors investigated TMD symptoms based on a questionnaire completed by 
a large sample of FM patients. Ninety-four percent of these patients described 
TMD pain which reportedly followed pre-existing FM pain of long duration. 
Patients also reported headache, facial pain, jaw fatigue and difficulty chewing 
and opening the mouth 128. Because of subjective reporting of TMD symptoms, 
the conclusion that FM causes TMD should be cautiously considered since 
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objective clinical findings were not performed and the design does not allow 
inference of comorbidity. FM and TMD share common symptoms such as 
generalized pain sensitivity, sleep and concentration difficulties and headaches 
135 which may influence symptom reporting. 
Plesh et al (1996) investigated prevalence and symptom severity of both 
FM and TMD among FM and TMD patients using the ACR and RDC for TMD 
criteria respectively. They concluded that these are separate disorders; however, 
FM patients commonly reported TMD symptoms but it was rarely the case that 
TMD patients reported FM 129. Eighteen percent of TMD patients fulfilled the FM 
criteria, whereas 75% of FM patients met the criteria for TMD. This study also 
revealed that FM patients had lower pain thresholds with more frequent and 
more severe symptoms such as pain, sleep disturbances, and fatigue than TMD 
patients. In addition, FM patients reported more functional disability, work 
difficulty and overall health dissatisfaction 129. In support of the study by Plesh et 
al (1996), Pennacchio et al (1998) revealed that 97% of FM patients had signs 
and symptoms of TMD. These signs and symptoms included pain or tenderness 
of the masseters, temporalis and TMJs, history of trauma, facial asymmetry, 
bruxism and limited range of mandibular movement. Contrary to the study by 
Plesh et al. (1996), Pennacchio et al. (1998) found that the type, intensity, 
description and quality of pain were similar in both TMD and FM patients 136. 
Therefore, it was suggested that FM and TMD share common symptoms 135. The 
extent of the relationship between FM and TMD based on these common 
symptoms needs to be studied further.   
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Cimino et al. (1998) compared clinical and psychological features of FM 
and masticatory myofascial pain syndrome patients. Clinical findings of muscle 
palpation did not reveal any difference between the two groups, nor were there 
differences in active and passive mouth opening. Similarly, both groups had 
elevations in psychological distress scores but there were no significant 
differences between the groups 137. 
Comorbidity between myofascial pain (myalgia) of FM and TMD has been 
reported as well.  In a study by Dao et al. (1997) which included myogenous 
TMD patients, many patients had pains in various body sites. Similarly, FM 
patients exhibited comparable facial pain to that of TMD patients. The authors 
suggested that FM should be a differential diagnosis for TMD patients with 
primary muscle complaints. In spite of these observations, FM was considered 
far more debilitating with respect to number of pain sites, somatic symptoms and 
level of pain intensity than was TMD. The authors suggested that TMD and FM 
are distinct clinical disorders 138. In addition, it was suggested that the presence 
of facial pain may be due to a decrease in pain threshold associated with FM, as 
proposed by Wolfe 94 138.       
According to Rhodus et al (2003), the prevalence of TMD based on a 
questionnaire among FM patients was 67.6% compared to 20% among controls. 
In addition, 60% of FM patients were depressed and anxious but this was not 
statistically different from controls with TMD 99. This was confirmed by an earlier 
study that reported presence of psychopathological profiles for depression and 
anxiety among FM patients and TMD patients 139.  
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The above studies imply a relationship between TMD and FM. However, 
the relationship is unclear as many of the studies were retrospective or 
observational, not blinded, uncontrolled, questionnaire based and, most often, 
had small sample sizes. Similarly, some of the studies did not use the ACR 
classification for FM and many studies did not define TMD or failed to use the 
RDC for TMD classification. If a clear relationship does exist between FM and 
TMD, it is likely related to the dysregulation of the HPA axis and dysfunction of 
the autonomic nervous system, as well as the disturbances in peripheral and 
central inhibitory control mechanisms 97 140. 
 
3.3.1. Summary 
This review highlights a relationship between FM and TMD. Although 
many uncertainties exist, signs and symptoms of TMD may be present in FM 
patients. It is therefore not unlikely that FM may be an etiologic factor for TMD. 
Based on these previous findings, this study will examine the presence of signs 
and symptoms of TMD in FM patients compared to failed back syndrome (FBS) 
patients as well as evaluate the differences in psychosocial distress.  
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Chapter 4. Experimental Design and Methods 
 
4.1. Participants  
This was a prospective study that involved recruiting patients visiting the 
Physical Medicine and Rehabilitation Clinic and patients from a FM workshop 
organized by the Center for the Advancement of Women’s Health at the 
University of Kentucky between March 2005 and April 2006. The research was 
approved by the Institutional Review Board for the Protection of Human Patients. 
The study sample included 32 FM and 19 FBS patients. The FM patients for the 
study had received a diagnosis by a physical medicine and rehabilitation 
specialist or rheumatologist, based on the criteria for the classification of FM as 
established by the ACR 94. The diagnosis of FBS was based on persistent or 
recurrent, chronic lower back pain after at least one failed surgical procedure of 
the lumbasacral spine 141 142 143. All interested patients were required to sign an 
informed consent and were compensated $20 for their time.  
 
4.2. Inclusion and Exclusion Criteria  
Patients who presented with the following characteristics were included in 
the study: 
1. At least 18 years of age. 
2. A primary diagnosis of FM or FBS.  
3. Pain duration of at least 6 months.  
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Patients who presented with the following characteristics were excluded 
from the study:  
 
1. Other chronic pains unrelated to the primary diagnosis. 
2. Uncontrolled metabolic diseases (e.g uncontrolled diabetes). 
3. Neurological disorders (e.g trigeminal neuralgia). 
4. Uncontrolled vascular diseases (e.g. uncontrolled hypertension). 
5. Neoplasia. 
6. Current psychiatric treatment. 
 
4.3. Questionnaires  
Prior to the examination, all patients were given an orofacial pain 
questionnaire and a battery of psychological assessments. The orofacial pain 
questionnaire included questions about the patient’s orofacial complaints and 
medical history. The psychological questionnaires included the Symptom Check 
List-90-revised (SCL-90-R) 144, the Pittsburgh Sleep Quality Index  (PSQI)  145, 
the Multi-dimensional Pain Inventory (MPI) 146, the Post-traumatic Stress 
Disorder Checklist-Civilian Version (PCL-C) 147, and Multidimensional Fatigue 
Symptoms Inventory-short form (MFSI-SF) 148. 
 
4.3.1. Orofacial Pain Questionnaire 
All patients completed this questionnaire which gathered demographic 
data, presence of face or headache pain, and medical history.  Patients with 
current face pain were required to provide details on its location, onset, severity, 
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quality, and aggravating and ameliorating factors. Presence of mouth pain, 
headache, and TMJ sounds and dysfunction were also solicited. Disability or 
intentions to seek disability was also established.    
In addition, the orofacial pain questionnaire included qualitative 
descriptors from the McGill Pain Questionnaire for self-report of the pain 
experience 149. These characterizations of pain are divided into sensory and 
affective classifications. The sensory category included terms such as throbbing, 
shooting, stabbing, and aching, while the affective category contained terms such 
as sickening, exhausting, and punishing (Appendix 1).  
 
4.3.2 Psychometric Measures 
The psychological questionnaires included the SCL-90-R 144, the PSQI 145 
the MPI 146, PCL-C 147, and MFSI-SF 148. 
The SCL-90-R 144 was used to assess current psychological symptom 
status of the patients on nine dimensions. These dimensions include:  
somatization, obsessive-compulsive behavior, interpersonal sensitivity, 
depression, anxiety, hostility, phobic anxiety, paranoid ideation, and 
psychoticism.  It consists of a 90-item multi-dimensional self-report inventory 
which is scored on a five-point scale of distress (0-4).  A subscale score ≥63 was 
deemed clinically significant. Test-retest reliabilities range from r = 0.78 to 0.90 
for non-patient samples, and internal consistencies range from 0.77 to 0.90 144.  
The MPI 146 was used to determine pain severity, as well as to provide a 
pain profile classification of each subject. It included three sections and contains 
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61 questions. The MPI pain profile classification is based on pain level, social 
and physical activities, affective distress, social support, and feelings of life 
control.  Test-retest reliabilities of the individual scale scores range from r = 0.68 
to 0.86, and internal consistencies range from 0.73 to 0.90 146. Patients were 
classified into three prototypic profiles namely dysfunctional, interpersonally 
distressed and adaptive copers. Patients who report a high level of pain, distress, 
and disability and who feel pessimistic and helpless about their condition are 
classified as dysfunctional. The interpersonally distressed category includes 
patients with the same characteristics as dysfunctional and in addition report 
poor social support. Patients who report low levels of pain, disability, and distress 
are classified as adaptive copers. Other classification categories include hybrid, 
anomalous and unanalyzable profiles. The hybrid profile represents a 
combination of prototypic profiles. The anomalous profile classification was used 
when no sense can be made of the MPI scale scores to establish a particular 
theory. Random responding, reading or responding difficulties, or faking bad or 
good responses contributes to allocation of the anomalous profile. When data are 
missing and statistical analyses of the scores are not possible the unanalyzable 
profile is allocated.  
 The PSQI 145 was used to gather information regarding the amount of 
hours the subject sleeps each night, the amount of hours in bed each night, how 
often the subject is awakened and why, as well as how difficult it is for the subject 
to return to sleep upon awakening. A PSQI total score of > 5 categorized 
subjects as poor sleepers. The PSQI has exhibited test-retest stability (full scale r 
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= 0.85), good overall internal consistency (α = 0.83), and provides a valid and 
reliable assessment of overall sleep quality and disturbance 145 150. 
 The PCL-C instrument includes 15 itemized statements about 
significant traumatic stressors that the subject may have experienced. The items 
listed include: military combat, violent attack, being kidnapped, taken hostage, 
terrorist attack, torture, incarceration, natural or man-made disaster, severe auto 
accident, being diagnosed with a life-threatening illness, sudden injury/serious 
accident, observed someone hurt or killed, learning that her/his child has a life-
threatening illness, and an others category. Subsequently, the subject is asked to 
identify the most significant stressor, indicate the date of occurrence and 
appraise how much the most significant stressor has bothered her/him in the past 
month on the 17-item measure. These questions are graded from 1 (not at all) to 
5 (extremely) to indicate the impact of the most significant traumatic stressor. 
Based on the subject’s answers a likely diagnosis of PTSD may be ascertained 
according to the DSM-IV. A cut-off score of ≥41 on the 17-item measure was 
deemed as PTSD positive and a score of <41 was deemed PTSD negative. The 
PCL-C has exhibited sensitivity = 0.85, specificity = 0.90, positive predictive 
power = 74%, negative predictive power = 95%, test-retest stability (r = 0.96), 
good overall internal consistency (alpha = 0.92), and provides a valid and reliable 
assessment of the presence of PTSD symptoms 151 147.   
The MFSI-SF identifies 5 facets of fatigue: 1) global experience of fatigue; 
2) somatic symptoms of fatigue; 3) cognitive symptoms of fatigue; 4) affective 
symptoms of fatigue; and 5) behavioral symptoms of fatigue 148. Each facet is 
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calculated from the mean of six sub-scores of fatigue-related symptoms. The 
shortened version (MFSI-SF) which consists of 30 statements was used for this 
study. Patients were asked to rate each statement according to how true it has 
been for them over the past 7 days along a 5-point scale (0 = not at all; 4 = 
extremely). There are no formal reliability and internal consistency data for this 
assessment. However, de Leeuw et al. (2005) reported high overall internal 
consistency for each of the subscales (.88 < alpha < 0.96) using a TMD patient 
population and age and sex healthy controls 152.      
 
4.4 Clinical Examination 
The orofacial pain examination involved a thorough clinical assessment by 
a dentist who was blinded to the clinical diagnosis of the patients. The dentist 
was unaware with regard to whether he examined a FBS or FM subject. The 
clinical examination was carried out using a modified version of the examination 
protocol that has been used at the University of Kentucky, Orofacial Pain Center 
for many years (Appendix 2). The dentist was trained at the Orofacial Pain 
Center and had performed numerous similar clinical examinations. Based on the 
clinical data and according to the RDC for TMD, a list of prioritized diagnoses 
were made 24. These diagnoses were verified by two other dentists trained at the 
University of Kentucky, Orofacial Pain Center. If there was a disagreement 
between the two dentists as to the RDC diagnoses for TMDs, a discussion was 
held among the three dentists and consensus as to the appropriate diagnoses 
was reached. 
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4.5 Statistical Analyses  
The analyses of the data involved comparing the FM and FBS patients. 
The sociodemographic data, namely age, was tested using the Student’s t-test. 
Gender, education, marital status, and smoking were tested using Fisher’s exact 
test, and employment and disability were tested using the Chi-square test.  
Comparison of the presence of orofacial pains between FM and FBS 
patients involved statistical analyses using SAS 9.1 (SAS Institute Inc.) namely 
the two sample t tests comparing mean scores between the two groups, or Chi-
square / Fisher’s Exact tests comparing the outcome percentages between the 
two groups were conducted. For the binary outcomes, odds ratio and 95% 
confidence interval of the odds ratio were calculated. In addition, further analysis 
for the comparison of the percent of patients meeting RDC for TMD criteria 
between patients who reported face pain and those who did not was tested using 
the Fisher’s Exact test and Chi-square test.  
Comparison of pain severity and pain duration between FM and FBS 
patients who reported face pain were tested using the two sample t-test. 
Similarly, comparison of SCL-90-R symptoms dimensions, MPI categories, 
MFSI-SF and PSQI scores between FM and FBS patients were also tested using 
the two sample t-test. Frequency of MPI profile classification among FM and FBS 
patients was tested using Fisher’s exact test and the Chi-square test. 
Comparison of the percentage of patients who reported a stressful life event and 
those who met the PTSD criteria between FM and FBS patients was tested using 
Fisher’s exact test. Pearson’s correlation was performed to determine 
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correlations between sleep disturbances and fatigue-related symptoms among 
FM and FBS patients. Significance level for all comparisons was set at P=.05. 
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Chapter 5. Results 
 
5.1 Sample size, Sociodemographic Characteristics, Prevalence, Severity 
and Duration of Temporomandibular Disorders  
The total sample was comprised of 51 adult patients (male = 6; female = 
45). The FM group comprised of 32 patients (male = 0; female = 32) with a mean 
age of 52.2 ± 7.8 years. The FM group (P=0.002) differed with respect to gender 
from the FBS group which comprised of 19 patients (male = 6; female = 13) with 
a mean age of 50.0 ± 9.1 years. The two groups also differed with respect to their 
education level (P=0.03), where a greater number of FM (40.5%) patients had 
college degrees in comparison to FBS (21%) patients. Tobacco use was 
significantly more prevalent among the FBS (42%) compared to FM (3%) 
patients (P<0.0001). There were no significant differences between the two 
groups in regard to age (P=0.36), marital status (P=0.60), employment (P=0.55), 
and disability (P=0.48; see table 3).  
Fifty three percent of the FM patients reported face pain compared to the 
11% of the FBS group (p=0.002). The FM patients were 9.6 times more likely to 
report face pain than the FBS group. The FM patients also reported a greater 
prevalence of headache (78%) compared to the FBS patients (63%) but this 
difference was not statistically significant (P=0.25). Almost the same percentage 
of FBS patients (42%) and FM patients (41%) reported mouth pain (see table 4).   
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Of the FM patients who reported face pain, 71% fulfilled the clinical RDC 
for TMD criteria. Of those FM patients who did not report face pain, 47% fulfilled 
the clinical RDC for TMD criteria. However, within the FM group, the patients who 
reported face pain were not significantly more likely to meet clinical RDC for TMD 
criteria compared to the patients who did not report face pain (P=0.17, odds 
ratio=2.74, 95%C.I.=0.64-11.75). Also, within the FBS group, the patients who 
reported face pain (50%) were not significantly more likely to meet the clinical 
RDC for TMD criteria compared to the patients who did not report face pain 
(12%) (P=0.30, odds ratio=7.5, 95%C.I.=0.32-173.28; see table 5). 
.   The various RDC for TMD diagnostic subcategories were allocated for 
both FM and FBS patients. No significant difference was found for any of the 
diagnostic subcategories between the two groups (P > 0.05; see table 6). 
Seventy four percent of the FM patients received a muscle diagnosis which 
included 32% myofascial pain and 42% myofascial pain with limited opening. 
Two out of the three FMS patients who met the RDC criteria for TMD received a 
muscle diagnosis and these two patients were diagnosed with myofascial pain 
with limited opening (66%). Twenty one percent of the FM patients were 
diagnosed with a disk displacement with reduction and this included any 
participant having internal derangements in either or both joints. Arthralgia was 
diagnosed in 16%, TMJ osteoarthritis in 26% and TMJ osteoarthrosis in 37% of 
the FM patients.  
Pain severity was measured based on a 0-10 visual analogue scale and 
reported as 5.2 ± 2.1 and 3.5 ± 0.7 for the FM and FBS patients respectively. 
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Pain duration was calculated to be the time in months from when the pain began 
through to the examination. Pain duration reported by patients was 50.3 ± 117.2 
and 53.5 ± 72.8 months for the FM and FBS patients respectively. No significant 
differences were found for mean pain severity and mean pain duration between 
FM and FBS patients (see table 7). 
 
5.2 Psychometric Data  
5.2.1 Symptom Check List-90-Revised 
 Analyses of SCL-90-R data revealed numerically higher scores on all 
subscales for FM as compared to FBS patients, although these differences were 
not statistically significant for most scales (see table 8). The FM patients had 
statistically significant higher scores for somatization (P=0.02) and obsessive-
compulsive (P=0.009) subscales compared to the FBS patients. The FM patients 
had clinically relevant subscale scores for somatization, obsessive-compulsive 
and depression, whereas the FBS patients had a clinically relevant subscale 
score for somatization. 
 
5.2.2 Multidimensional Pain Inventory Profile Classification 
The FM patients had numerically higher scores on “pain severity”, 
“interference”, “affective distress”, “punishing responses”, “household chores”, 
“outdoor work”, and “activities away from home” scales and had lower scores on 
“life control”, “support”, “soliciting responses”, “distracting responses”, “social 
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activities”, and “general activities level” scales than the FBS patients. However, 
these differences were not statistically significant (P>0.05; see table 9). 
When possible, patients were classified in one of the three main MPI 
profiles. Twenty five percent of the FM patients were classified as “dysfunctional”, 
31% were classified as “interpersonally distressed” and 28% were classified as 
“adaptive copers”. No significant differences (P>0.05) were found between the 
FM patients and the FBS patients with regard to the MPI main profile 
classification (see table 10).  
 
5.2.3 Pittsburgh Sleep Quality Index 
Both FM and FBS patients had elevated PSQI total scores suggesting 
poor sleep but there was no significant difference between the two groups. The 
mean score for “use of sleep medication” was significantly different between the 
FM and FBS patients (P=0.002) whereby the FM patients had a higher score for 
sleep medication use than the FBS patients. None of the other PSQI scales 
showed significant differences between the FM and FBS groups (see table 11).  
 
5.2.4 Post-traumatic Stress Disorder Checklist- Civilian Version  
There were significant differences between the FM and FBS groups in the 
percentage of patients reporting a stressful life event (P=0.04, odds ratio=5.2, 
95% C.I.=1.28-21.18). Eighty seven percent of FM patients reported a stressful 
life event compared to 56% of FBS patients. FM patients were 5.2 times more 
likely to report a stressful life event compared to FBS patients (see table 12). 
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Of the FM patients who reported a stressful life event, 42.3% were 
deemed PTSD positive compared to 30% of the FBS patients. However, there 
was no statistical evidence that FM patients were more likely to have PTSD 
positive symptoms than FBS patients (P=0.71, odds ratio=1.71, 95% C.I.=0.36-
8.15) (see table 13).   
 
 5.2.5 Multidimensional Fatigue Symptoms Inventory-short form 
FM patients had significantly higher general fatigue (P<0.0001), emotional 
fatigue (P=0.008), physical fatigue (P<0.0001) and mental fatigue (P<0.0001) 
than FBS patients. The FBS patients had a higher vigor score than the FM 
patients but this difference was not statistically significant (see table 14). 
It appears that among the FBS patients the PSQI total score, sleep 
latency, sleep duration, sleep efficiency, sleep disturbances, and daytime sleep 
dysfunction are correlated with one ore more fatigue related symptoms (P<0.05; 
see table 15). Among FM patients, it appears that the PSQI total score, 
subjective sleep quality, sleep latency, sleep duration and sleep efficiency are 
correlated with one or more fatigue related symptoms (P<0.05; see table 16).  
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Table 3: Comparison of Sociodemographic Characteristics between FM  
and FBS Patients. 
 FM (n=32) 
 n (%) 
FBS (n=19) 
 n (%) 
P 
Age a    
   Mean±SD 52.2±7.8 50.0±9.1 0.36 
   Range 35-72 34-65  
    
Gender b   0.002* 
   Male 0 (0%) 6 (32%)  
   Female 32 (100%) 13 (68%)  
    
Marital Status b   0.60 
   Single 4 (12.5%) 3 (16%)  
   Married 24 (75%) 12 (63%)  
   Divorced 4 (12.5%) 3 (16%)  
   Widowed 0 (0%) 1 (5%)  
       
Employed c   0.55 
   Yes 11 (34%) 5 (26%)  
   No 21 (66%) 14 (74%)  
    
Education b   0.03* 
 High school 14 (44%) 8 (42%)  
 Associate or Technical 5 (16%) 5 (26%)  
 BS/BA 9 (28%) 0 (0%)  
 Graduate Degree or         
 Professional Degree 
4 (12.5%) 4 (21%)  
 None of the Above  0 (0%) 2 (11%)  
    
Disability c   0.48 
  Yes 17 (53%) 12 (63%)  
  No 15 (47%) 7 (37%)  
    
Tobacco Use b   <0.0001* 
  Yes 1 (3%) 8 (42%)  
  No 31 (97%) 11 (58%)  
                 a t test assuming unequal variance 
                 b Fisher’s exact test 
                 c Chi-square test 
n=number of patients  
%=percentage 
SD=standard deviation 
* Statistical significant difference 
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  Table 4: Comparison of Presence of Orofacial Pains between FM and FBS Patients. 
Outcome FM 
(n=32) 
 n (%) 
FBS 
(n=19) 
 n (%) 
P+ Odds Ratio of FM vs. 
FBS (95% C.I.) 
Reported Face Pain    0.002* 9.6 (1.9-48.7) 
   Yes 17 (53%) 2 (11%)   
   No 15 (47%) 17 (89%)   
     
Reported Mouth 
Pain 
  0.92 0.94 (0.30-3.0) 
   Yes 13 (41%) 8 (42%)   
   No 19 (59%) 11 (58%)   
     
Reported Headache   0.25 2.1 (0.6-7.3) 
  Yes 25 (78%) 12 (63%)   
  No 7 (22%) 7 (37%)   
   * Statistical significant difference  
    + Chi-square test 
   %=Percentage 
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Table 5: Comparison of FM and FBS Patients who Reported Face Pain to  
those who did not Report Face Pain (for patients who met the Clinical RDC  
for TMD Criteria). 
Group Outcome Reported 
Face 
Pain  
 n (%) 
Did Not 
Report Face 
Pain  
N (%) 
P Odds Ratio
 (95% C.I.) 
FM Met RDC for TMD 
Criteria a, b 
  0.17 2.7 (0.6-
11.8) 
(n=32)    Yes 12 (71%) 7 (47%)   
    No 5 (29%) 8 (53%)   
      
FBS Met RDC for TMD 
Criteria or Not c  
  0.30 7.5 (0.3-
173.3) 
(n=19)    Yes 1 (50%) 2 (12%)   
    No 1 (50%) 15 (88%)   
a pertains to the clinical findings that fulfilled the RDC for TMD criteria  
b Chi-square test  
c Fisher’s exact test  
n=number of patients 
%=percent 
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Table 6: Comparison of TMD Diagnoses between FM and FBS Patients (for     
Patients who met Clinical RDC for TMD) 
TMD Diagnosis FM 
(n=19) 
FBS  
(n=3) 
P * Odds Ratio 
 (95% C.I.) 
Myofascial Pain b   0.53 NA 
   Yes 6 (32%) 0 (0%)   
   No 13 (69%) 3 (100%)   
     
Myofascial Pain With Limited 
Opening  b 
  0.57 0.36 (0.03-4.7) 
   Yes 8 (42%) 2 (67%)   
   No 11 (58%) 1 (33%)   
     
Disk Displacement With Reduction 
b 
  1.00 NA 
   Yes 4 (21%) 0 (0%)   
   No 15 (80%) 3 (100%)   
     
Disk Displacement Without 
Reduction, With Limited Opening b 
  1.00 NA 
   Yes 0 (0%) 0 (0%)   
   No 19 
(100%) 
3 (100%)   
     
Disk Displacement Without 
Reduction, Without Limited 
Opening b  
  1.00 NA 
   Yes 0 (0%) 0 (0%)   
   No 19 
(100%) 
3 (100%)   
     
Arthralgia b   0.47 0.38 (0.03-5.8) 
   Yes 3 (16%) 1 (33%)   
   No 16 (84%) 2 (67%)   
     
Osteoarthritis of the 
Temporomandibular Joint b 
  1.00 NA 
   Yes 5 (26%) 0 (0%)   
   No 14 (74%) 3 (100%)   
     
Osteoarthrosis of the 
Temporomandibular Joint b 
  1.00 1.2 (0.09-15.3) 
   Yes 7 (37%) 1 (33%)   
   No 12 (63%) 2 (67%)   
* Fisher’s exact test 
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NA=not available due to zero frequencies 
n=number of patients 
%=percentage 
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Table 7: Comparison of Pain Severity and Pain Duration between FM and FBS Patients 
who Reported Face Pain. 
Outcome Group n Mean SD P* 
Pain Severity (0-10)  FM 17 5.2 2.1 0.29 
 FBS 2 3.5 0.7  
      
Pain Duration 
(Month) 
FM 17 50.3 117.2 0.97 
 FBS 2 53.5 72.8  
* two sample t test 
n=number of patients 
SD=standard deviation 
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 Table 8: Comparison of SCL-90-R Symptom Dimensions between FM and FBS    
  Patients.  
SCL-90-R 
Symptom 
Dimensions 
Group n Mean SD P+ 
      
Somatization FM 31 70.5 7.9 0.02* 
 FBS 19 65.0 8.2  
      
Obsessive-
Compulsive 
FM 31 69.7 10.4 0.0009*
 FBS 19 60.1 8.6  
      
Interpersonal 
Sensitivity 
FM 31 60.8 9.8 0.052 
 FBS 19 54.1 14.2  
      
Depression FM 31 64.4 9.0 0.37 
 FBS 19 61.8 10.8  
      
Anxiety FM 31 61.3 11.6 0.17 
 FBS 19 56.4 13.1  
      
Hostility FM 31 56.6 10.9 0.30 
 FBS 19 53.1 12.0  
      
Phobic Anxiety FM 31 55.2 12.1 0.63 
 FBS 19 53.7 8.1  
      
Paranoid Ideation FM 31 56.6 12.0 0.36 
 FBS 19 53.5 11.4  
      
Psychoticism FM 31 60.0 10.9 0.72 
 FBS 19 58.9 8.6  
   + two sample t test 
  n=number of patients 
  SD=standard deviation 
  * Statistically significant difference 
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   Table 9: Comparison of MPI Categories between FM and FBS Patients.  
MPI Scale Group n Mean SD P* 
      
Part I      
  Pain Severity FM 32 46.0 11.1 0.08 
   FBS 19 39.5 14.9  
      
  Interference FM 32 46.7 10.3 0.47 
 FBS 19 44.4 12.5  
      
  Life Control FM 32 49.3 7.0 0.19 
 FBS 19 52.2 8.3  
      
  Affective Distress FM 32 46.9 7.6 0.059  
 FBS 19 42.0 10.5  
      
  Support FM 29 43.6 10.1 0.29 
 FBS 18 46.7 8.4  
      
Part II      
   Punishing Responses FM 30 51.4 10.2 0.065  
 FBS 18 46.2 7.0  
      
  Soliciting Responses FM 30 48.2 10.1 0.11 
 FBS 18 52.6 7.4  
      
  Distracting Responses FM 30 45.4 8.8 0.33 
 FBS 18 47.8 7.3  
      
Part III        
  Household Chores FM 32 54.8 10.0 0.17 
 FBS 19 51.1 8.4  
      
  Outdoor Work FM 32 51.5 8.3 0.09 
 FBS 19 47.4 7.6  
      
Activities Away From 
Home 
FM 32 50.9 9.7 0.63 
 FBS 19 49.6 8.2  
      
  Social Activities FM 32 45.0 9.8 0.32 
 FBS 19 47.3 6.0  
      
  General Activity Level FM 32 51.3 8.7 0.30 
 FBS 19 48.7 8.1  
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* two sample t test 
n=number of patients 
SD=standard deviation 
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      Table 10: Comparison of MPI Profile Classification between FM and FBS    
       Patients.  
MPI Classes FM 
(n=32) 
FBS  
(n=19) 
P  Odds Ratio 
 (95% C.I.) 
     
Dysfunctional c   0.61 0.72 (0.21-2.5) 
   Yes 8 (25%) 6 (32%)   
   No 24 (75%) 13 (68%)   
     
Interpersonally 
Distressed b 
  0.17 3.9 (0.75-20.0) 
   Yes 10 (31%) 2 (11%)   
   No 22 (69%) 17 (49%)   
     
Adaptive Coper c   0.52 0.67 (0.20-2.3) 
   Yes 9 (28%) 7 (37%)   
   No 23 (72%) 12 (63%)   
          b Fisher’s exact test. 
          c Chi-square test. 
       N=number of patients 
       %=percentage 
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    Table 11: Comparison of PSQI Scores between FM and FBS Patients. 
PSQI Score Group Mean SD P+ 
     
PSQI Total Score FM 12.9 3.9 0.45 
 FBS 12.0 4.6  
     
Subjective Sleep Quality FM 1.8 10 0.77 
 FBS 1.7 0.7  
     
Sleep Latency FM 1.9 0.9 0.59 
 FBS 2.1 10  
     
Sleep Duration FM 1.7 0.9 0.21 
 FBS 2.1 0.9  
     
Sleep Efficiency FM 1.3 1.2 0.20 
 FBS 1.8 1.3  
     
Sleep Disturbances FM 2.0 0.7 0.10 
 FBS 1.7 0.5  
     
Use of Sleep Medication FM 2.4 1.0 0.002* 
 FBS 1.3 1.3  
     
Daytime Sleep 
Dysfunction 
FM 1.8 1.0 0.06 
 FBS 1.3 1.0  
        + two sample t test 
     SD=standard deviation 
     * Statistically significant difference 
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Table 12: Comparison of Reported Stressful Life Events between FM and  
FBS Patients. 
Reported a Stressful Life 
Event 
FM 
(n=30) 
FBS  
(n=18) 
P* Odds Ratio (95% 
C.I.) 
     
   Yes 26 (87%) 10 (56%) 0.036 5.2 (1.3-21.2) 
    No 4 (13%) 8 (44%)   
* Fisher’s exact test 
n=number of patients 
%=percentage 
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     Table 13: Comparison of PTSD Symptoms between FM and FBS Patients who    
     Reported Stressors. 
PTSD Symptoms FM 
(n=26) 
FBS  
(n=10) 
P* Odds Ratio (95% 
C.I.) 
     
   Positive 11 (42.3%) 3 (30%) 0.71 1.7 (0.36-8.2) 
   Negative 15 (57.7%) 7 (70%)   
      *Fisher’s exact test 
      n=number of patients  
      %=percentage 
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  Table 14: Comparison of Fatigue-related Symptoms (MFSI-SF) between FM and FBS     
   Patients  
Fatigue-related 
Symptoms 
Group n Mean SD P+ 
      
General FM 32 3.1 0.8 <0.0001*
 FBS 19 1.8 1.1  
      
Emotional FM 32 2.1 1.0 0.008* 
 FBS 19 1.2 1.0  
      
Physical FM 32 2.6 0.8 <0.0001*
 FBS 19 1.4 0.9  
      
Mental FM 32 2.4 1.0 <0.0001*
 FBS 19 1.1 0.8  
      
Vigor FM 32 1.3 0.7 0.15 
 FBS 19 1.6 0.8  
    + two sample t test. 
   N=number of patients 
   SD=standard deviation     
   * Statistically significant difference 
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Table 15: Correlations between PSQI Scores and Fatigue-related Symptoms  
(MFSI-SF) among FBS Patients. 
Variable 
General 
(n) 
(correlation+)
(P) 
Emotional 
(n) 
(correlation+)
(P) 
Physical 
(n) 
(correlation+)
(P) 
Mental 
(n) 
(correlation+) 
(P) 
Vigor 
(n) 
(correlation+)
(P) 
  
 19 19 19 19 19
PSQI Total Score 0.45 0.50 0.55 0.50 -0.44
  0.053 0.03* 0.02* 0.03* 0.06
  
 19 19 19 19 19
 Subjective Sleep Quality 0.27 0.28 0.32 0.42 -0.07
  0.26 0.25 0.19 0.07 0.78
  
 19 19 19 19 19
Sleep Latency 0.08 0.46 0.40 0.08 -0.22
  0.74 0.047* 0.09 0.73 0.36
  
 19 19 19 19 19
 Sleep Duration 0.34 0.38 0.56 0.39 -0.28
  0.15 0.11 0.01* 0.10 0.25
  
 19 19 19 19 19
Sleep Efficiency 0.35 0.32 0.46 0.46 -0.45
  0.14 0.18 0.046* 0.0496* 0.06
  
 19 19 19 19 19
Sleep Disturbances 0.33 0.22 0.52 0.23 -0.54
  0.17 0.36 0.02* 0.35 0.02*
  
 19 19 19 19 19
 Use of Sleep Medication 0.27 0.31 0.05 0.16 -0.24
  0.26 0.19 0.85 0.52 0.32
  
 19 19 19 19 19
Daytime Sleep Dysfunction 0.49 0.36 0.48 0.64 -0.35
 0.03* 0.12 0.04* 0.003* 0.14
* Statistically significant difference 
+ Pearson’s correlation 
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Table 16: Correlations between PSQI Scores and Fatigue-related Symptoms (MFSI-SF) 
among FM patients. 
Variable 
General 
(n) 
(correlation+)
(P) 
Emotional 
(n) 
(correlation+)
(P) 
Physical 
(n) 
(correlation+)
(P) 
Mental 
(n) 
(correlation+) 
(P) 
Vigor 
(n) 
(correlation+)
(P) 
        
  32 32 32 32 32
PSQI Total Score 0.50 0.43 0.40 0.45 -0.28
  0.004* 0.01* 0.02* 0.01* 0.11
       
  32 32 32 32 32
Subjective Sleep Quality 0.41 0.15 0.19 0.08 -0.15
  0.02* 0.40 0.31 0.65 0.42
       
  32 32 32 32 32
Sleep Latency 0.35 0.37 0.25 0.59 -0.15
  0.0499* 0.04* 0.17 0.0004* 0.41
       
  31 31 31 31 31
Sleep Duration 0.50 0.33 0.23 0.19 -0.30
  0.004* 0.07 0.22 0.30 0.10
       
  31 31 31 31 31
Sleep Efficiency 0.38 0.17 0.06 0.27 -0.15
  0.03* 0.36 0.74 0.14 0.42
       
  32 32 32 32 32
Sleep Disturbances 0.18 0.28 0.23 0.22 -0.24
  0.33 0.12 0.21 0.24 0.18
       
  32 32 32 32 32
Use of Sleep Medication 0.09 0.24 0.31 0.34 -0.04
  0.63 0.18 0.08 0.06 0.82
       
  32 32 32 32 32
Daytime Sleep Dysfunction 0.21 0.21 0.33 0.15 -0.23
  0.25 0.24 0.06 0.41 0.21
* Statistically significant difference 
+ Pearson’s correlation 
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Chapter 6. Discussion 
 
  
This study investigated the prevalence of symptoms and signs of TMD in 
FM patients compared to another chronic pain patient sample, namely FBS. Fifty 
three percent of the FM patients compared to 11% of the FBS patients reported 
face pain. In this study FM patients were 9.6 times more likely to report face pain 
than the FBS patients. The greater prevalence of face pain among FM patients 
compared to FBS patients seems logical based on the definition of FM as a form 
of non-articular rheumatism characterized by widespread muscle pain, 
tenderness to palpation and stiffness of the locomotor system 94. It seems 
reasonable that FM may encompass TMD, which is a collective term embracing 
a number of clinical problems that involve the masticatory musculature, the TMJ 
and associated structures 8. Other studies have reported facial pain prevalence 
between 68-97% in FM patients 99 128 138 136.   
Of the FM patients who reported face pain, 71% met the clinical RDC 
criteria for TMD. The prevalence of TMD among FM patients in the current study 
is consistent with a study by Plesh et al. that reported that 75% of FM patients 
met the RDC criteria for TMD 129. Interestingly, 47% of FM patients who did not 
report face pain also had the relevant signs meeting the clinical RDC criteria for 
TMD. Previous studies have reported incongruence between reported TMD 
symptoms and the clinical finding of TMD signs. Patients may not report non-
troublesome symptoms, whereas the clinician may find signs that are clinically 
significant 9 34. Therefore, prevalence values of previous TMD studies may 
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overstate the clinical significance of the patient complaints and thus mild and/or 
transient symptoms and signs may inadvertently be misinterpreted and lead to 
over treatment 8. Alternatively, failure to report face pain among FM patients who 
had TMD signs may be due to the fact that these patients may have assumed or 
had been previously informed that their face pain was an extension of the FM 
pain, rather than a separate entity.  
FM patients who met the clinical criteria for RDC muscle diagnoses 
included 32% who had myofascial pain and 42% who had myofascial pain with 
limited opening. Therefore, muscle pain was diagnosable in 74% of the FM 
patients. This prevalence of muscle pain among FM patients was lower than had 
been previously reported in other studies 99 129 128 138. This may be due to the 
examiner in this study being blinded as to primary diagnosis (FM or FBS) of the 
recruited patients, therefore diminishing possible selection bias. In addition, many 
of the previous studies did not use the RDC for TMD criteria and rather relied on 
patient reported symptoms alone 128 138 or carried out clinical examination without 
established diagnostic criteria 99. 
Disk displacement with reduction was diagnosed among 21% of FM 
patients. It should be noted that this diagnosis included painless clicking of the 
TMJ that may be coincidental and not clinically relevant to FM. It has been 
reported that disk displacement with reduction, which includes clicking of the 
TMJ, may occur in a third of asymptomatic patients and therefore should not be 
used as an exclusive sign of the presence of TMDs requiring treatment 153.  
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Arthralgia was diagnosed in 16% of the FM patients and TMJ 
osteoarthritis was diagnosed in 26% of FM patients. Therefore, 42% of TMJs of 
FM patients were painful on palpation and during function. A previous study, 
reported that 80% of FM patients had pain or tenderness upon palpation of the 
TMJ. However, this study did not use the RDC criteria for TMD and therefore 
comparisons with our results were not possible 136. Osteoarthrosis of the TMJ 
was diagnosed in 37% of FM patients. This may be an underestimation as 
radiographic imaging of the TMJs, was not performed. Therefore, TMJs that 
”exhibit erosion of normal cortical delineation, sclerosis of parts or all of the 
condyle and articular eminence, flattening of joint surfaces and osteophyte 
formation that did not exhibit crepitus” 24 may have been missed and this could 
potentially lead to an underdiagnosis of TMJ osteoarthrosis in the present 
sample.  
Previous studies have highlighted significant psychological symptoms 
among FM patients 154 118 115. The FM patients had elevated SCL-90-R scores on 
somatization, obsessive-compulsive, and depression symptoms subscales as 
defined by a subscale score ≥63. Of interest were elevated subscale scores 
among FM patients for somatization (P=0.02) and obsessive-compulsive 
(P=0.009) compared to the FBS group. Studies comparing psychosocial findings 
between patients with FM and patients with rheumatoid arthritis suggested an 
association between FM and somatization 155 121 and obsessive compulsiveness 
119.  It has been established that FM patients present with multiple symptoms 
given the comorbidities associated with the syndrome, i.e. pain, sleep 
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disturbances, fatigue, etc. 5 7. The multiple symptoms of FM may be expressed 
as somatization and this in turn results in an internal focus on one’s health. The 
reverse is also likely whereby internal focus on one’s health may lead to 
somatization. This preoccupation with internal somatic states may manifest itself 
as elevations of depression and obsessive-compulsive symptoms in an attempt 
to cope with the FM symptoms. It would not be surprising that obsessive-
compulsive symptoms may represent cognitive and behavioral adaptation to 
pain. Compromised cognitive, affective and behavioral responses could result 
from excessive long-term preoccupation with one’s health. This may lead to 
dysregulatory psychopathology and maladaptive behavioral responses 156. In 
turn, maladaptive behavioral responses may lead to maladaptive physiological 
response which is understood to be a failure in inhibitory control and therefore 
perpetuate the symptoms of FM  114 71 157 158.  
The combination of the autonomic, attentional and affective systems into a 
dynamic functional and structural network enables the living system to self-
organize 71 114.  As described by Thayer and Lane (2000), these systems are 
likely modulated by inhibitory processes which in turn enable sustained 
functioning of the living system when confronted by stressors. Hence, in a 
compromised system such as that of FM patients, dis-inhibition (inhibitory failure) 
in the face of changing environmental demands may lead to maladaptive 
behavior which in turn, may hinder recuperation and normal functioning 114. The 
lack of significant differences among other SCL-90-R subscales between the two 
groups may be due to the fact that both FM 118 115 and FBS 159 160 are chronic 
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debilitating conditions that are frequently associated with psychosocial 
symptoms.  
 In the present study, FBS patients exhibited an elevation of the 
somatization score on the SCL-90-R. Previous studies have suggested that 
abnormal preoperative psychological features including depression, hysteria, 
hypochondriasis, conversion and somatization may predispose patients to 
greater post-operative pain after lumbar disk surgery 161. Others have suggested 
that FBS patients have “emotional problems” including elevated depression and 
somatic pain scores 162 163. Numerous studies have suggested poor outcomes 
involving reoperation of FBS patients with psychological problems 164 165 166 167. 
Therefore, it is not surprising that FBS patients in the present study exhibited 
elevation of the somatization subscale score on the SCL-90-R.    
Based on the PSQI total score, both the FM and FBS patients were 
considered poor sleepers defined by a PSQI total score of >5. Previous studies 
have associated poor sleep quality with FBS 168 169. It has been postulated that 
poor sleep may contribute to the pain complaint of FBS 169.  Further studies on 
sleep disturbances are needed to understand its role in FBS. On the other hand, 
it has been well established that FM patients frequently complain of disturbed, 
non-refreshing sleep 96 1. Likewise, healthy patients may express FM-like 
symptoms if their normal sleep architecture is disturbed 127. It is not understood 
whether increased pain in FM patients may contribute to sleep disturbances or 
sleep disturbances may result in increased pain among FM patients 79. 
Interestingly, apart from FM patients having a significantly larger score for use of 
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sleep medication, both groups of patients were not different with respect to all 
other PSQI scores. Use of sleep medication among FM patients is common and 
often prescribed as part of the treatment for poor sleep related to FM. Sedatives, 
such as benzodiazepines, zolpidem tartrate, zaleplon, antidepressants, such as 
amitriptyline and muscle relaxants, such as cyclobenzaprine, are often used to 
improve sleep 170 171 172 Therefore, the implied causative relationship of FM 
symptoms with poor sleep (architecture) could explain the higher use of sleep 
medications endorsed by FM patients compared to FBS patients.  
There is a strong relationship between sleep and chronic pain 79 80 81 82. A 
previous study reported that stage-four deprivation led to muscle tenderness and 
stiffness in healthy subjects, but such musculoskeletal symptoms were not 
observed following disruption of the rapid eye-movement (REM) sleep. Therefore 
poor sleep quality of the deeper sleep stages may be linked to chronic pain 
conditions. This may be a consequence of the failure to restore the functions of 
the body systems such as metabolic processes that occur in deeper sleep stages 
84. Although speculative, poor deep sleep quality may lead to musculoskeletal 
pain, which in turn, may contribute to a fragmented sleep cycle.  
Previous literature suggests that PTSD may coexist with FM 173 174. 
Suggestions that the two entities exist because of care seeking selection bias 
among FM patients, failure of FM patients to cope with life stress and 
confounding arousal symptoms between PTSD and FM has been refuted 175. 
Although exploratory, it is likely that FM and PTSD share psychobiological risk 
factors 175. A significantly higher number of FM patients (87%; P=0.036) than 
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FBS patients (56%) reported a stressful life event. Of those FM patients who 
reported a stressful life event, 42.3% were PTSD positive based on a score of 
greater than 41 on the PCL-C. Previous studies reported that more than 50% of 
FM patients had significant levels of PTSD symptoms 174 173. Sherman et al. 
found in a sample of FM patients that pain level, disability and affective distress 
was greater in those patients reporting PTSD symptoms than those who did not 
report such symptoms. Sherman and colleagues suggested that PTSD-like 
symptoms may influence the adaptative ability of FM patients. Therefore, failure 
to assess the presence of these symptoms may impede successful outcomes 173. 
Further studies are required to elucidate the relationship between FM and PTSD.  
  Presence of fatigue-like symptoms among FM patients has been 
previously reported 96 1 135 7. FM patients had significantly higher general, 
emotional, physical and mental fatigue scores than FBS patients. FM has been 
shown to have comorbidity with chronic fatigue syndrome, and patients often 
share common symptoms 176 177 178 135 179 180. Both conditions are marked by a 
heightened sensitivity to physical and psychological stress 96 97 7 98. Previous 
studies have revealed that fatigue in chronic pain was related to symptoms of 
somatization and depression and to a far lesser degree sleep disturbances 152 
181. In fact, it has been reported that somatization 152 181 and depression 181 are 
major predictors of fatigue.  It is likely that the multiple symptoms of FM such as 
wide spread pain, fatigue, sleep disturbances etc. may be the result of high 
somatization and depression scores in FM. That is, preoccupation with one’s 
health may manifest as elevations of depression and somatization symptoms in 
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an attempt to cope with the FM symptoms. The failure to cope may result in 
dysregulation of autonomic nervous system and in turn compromised cognitive, 
affective and behavioral responses apparent as fatigue-like symptoms 182 156. 
Maladaptive behavioral responses may lead to maladaptive physiological 
response and therefore perpetuate the fatigue-like symptoms of FM 157 158. 
Interestingly, sleep disturbances are frequently reported by chronic pain patients 
but are not thought to be the cause of fatigue 181. Both the FM and FBS patients 
had sleep disturbances based on the PSQI but there were no significant 
differences between the two groups. However, the FM patients were significantly 
more fatigued than the FBS patients. Interestingly, both FM and FBS patients 
revealed correlations between one or more PSQI scores and fatigue-related 
disturbances. This study is not in agreement with previous studies that suggests 
that fatigue is unrelated to quantitative measures of sleep 181 183.    
The high prevalence of TMDs and psychosocial distress among FM 
patients could be manifestations of either a dysfunctional HPA axis, and/or a 
dysregulated autonomic nervous system and in turn results in alterations of the 
peripheral and central pain facilitation and inhibitory pain mechanisms 97 140. 
Therefore, a facilitation or failure in inhibition of nociception may lead to central 
sensitization and increased pain perception. This in turn may affect the dynamic 
equilibrium of the system and shift it from an adaptive physiological state to that 
of dysfunction and pathology 114 71. This may further explain the comorbidity of 
FM with other conditions such as chronic fatigue syndrome, IBS and interstitial 
cystitis, which may be related to a reduction in pain threshold and tolerance 
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mediated by central nervous system mechanisms. In addition, these conditions 
are marked by a heightened sensitivity to both physical and psychological stress 
96 97 7 98. Therefore, the multiple symptoms presentation of FM, which may 
include pain, non-restorative sleep, fatigue, depression, obsessive-
compulsiveness, and somatization, is likely influenced by maladaptive 
physiological states.  
The sociodemographic data revealed that all FM patients were females 
and this was significantly different when compared to the FBS patients. This is 
consistent with other reports that suggest FM is more prevalent among women 1 
94. The mean age of FM patients in this study was 52 years and other studies 
have suggested a similar age distribution of FM among women in the general 
population 94 2 184.  
Sixty-six percent of the FM patients were unemployed and 53% were 
receiving disability. Previous studies have reported that 30% of FM patients 
worked shorter hours or less physically demanding jobs and 15% received 
disability from inability to work 185 91 92. Another study reported that 41% of 
patients were unable to work 129. The large number of unemployed subjects and 
subjects receiving disability in the current study may be a result of the 
recruitment protocol. Patients in this study were recruited from a Physical 
Medicine and Rehabilitation clinic and a FM workshop possibly targeting subjects 
who are actively seeking treatment and who may have greater severity of the 
condition.  
                                               64
A previous study reported that 22% of FM patients smoke tobacco and the 
study adjusted for age and education level 186. Interestingly, in the current study 
only one FM patient used tobacco and this was significantly different compared 
to FBS patients. Recent data on the prevalence of smoking in the United States 
reported that 23.4% of males and 18.5% of females in the total population smoke 
187. Therefore, a rational explanation of the low prevalence of tobacco use among 
FM patients in this study is difficult. Further research on the use of tobacco 
among FM patients is required to establish its prevalence. Interestingly, 42% of 
the FBS patients in this study used tobacco. It has been suggested that heavy 
tobacco use is common among FBS patients 142 and is a major risk factor for 
developing lower back pain 188 189 as well as failure of bony union associated with 
FBS 190.  
The present study has limitations in spite of its prospective design. A 
major concern of this study was the small sample sizes in each of the groups. 
Therefore, detailed statistical analysis of the study variables was not possible. 
Another major concern was that the study involved FBS patients as a control 
group which many consider a poorly defined clinical condition 141 142 143. Similarly, 
much debate persists on whether FM as a clinical condition exists. As a result, 
comparisons between two poorly defined conditions may have led to 
questionable findings and interpretation. On the other hand this was the first 
study that investigated the prevalence of TMDs in FM that employed a chronic 
pain population sample for comparisons. 
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Because of the recruitment protocol, the participating patients may not 
represent a sample of the general population. All patients were actively seeking 
treatment for their condition at a tertiary care center and this may have resulted 
in an overestimation of the prevalence of TMDs among FM patients. In addition, 
the prevalence of psychosocial distress in both FM and FBS patients may not be 
a representative of the subjects with these conditions in the general population. 
Therefore, the patients in this study could represent a selective pain population 
compared to those patients seen at a general practice.  
With respect to the prevalence of TMD, the RDC embraces all TMD 
diagnoses, including painless clicking and crepitation of the TMJs. As previously 
discussed, asymptomatic clicking of the TMJ and TMJ crepitation without 
imaging evidence of condylar bone remodeling may be coincidental and not be of 
clinical relevance. Therefore, this may have led to an overestimation of the 
prevalence of TMDs in FM patients. 
Finally, the subjects in this study were required to complete a history form 
that was not verified in an interview. Hence, errors in reporting may have 
occurred. Additionally, since the examiner was blind to diagnostic category, 
further verification of the information supplied by the patient was not accessible 
at the time of the clinical examination. Similarly, the blinded examination was 
performed by one dentist who was not calibrated in accordance to the RDC for 
TMD 191 192 193. Therefore, the reliability of the clinical finding was not determined. 
However, the clinical findings were verified by two other dentists trained at the 
University of Kentucky, Orofacial Pain Center. If there was a disagreement 
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between the two dentists as to the RDC diagnoses for TMDs, a discussion was 
held between the two dentists and the dentist that performed the blind 
examination and consensus as to the appropriate diagnoses was reached. 
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Chapter 7. Conclusion 
 
 
The present study replicates and extends previous investigations 
addressing the relationship between TMD and FM. Fifty three percent of FM 
patients reported face pain. Of those FM patients who reported face pain, 71% 
fulfilled the RDC criteria for TMD. Interestingly, 47% of FM patients who did not 
report face pain also fulfilled the RDC criteria for TMDs. Therefore, this study 
confirms our hypothesis that the prevalence of TMD is greater among FM 
patients than among FBS patients. Both the FM and FBS patients reported high 
levels of psychosocial distress, but somatization, obsessive compulsive, fatigue 
and medication needed for sleep disturbances were significantly higher for FM 
patients than for FBS patients. Eighty seven percent of the FM patients also 
reported a stressful event and approximately 42% of these patients were PTSD 
positive. These results suggest that a dysfunctional HPA axis and dysregulation 
of the autonomic nervous system are linked to the high prevalence of TMD and 
significant psychosocial distress among FM patients.  
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Appendix 1: Orofacial Pain Questionnaire Form 
 
ID __________ 
 
Date_____________ 
 
Your reason for visiting the clinic today?   [  ] Fibromyalgia    [  ] Lower back pain 
 
Age:___________ Date of Birth:__________________ Sex: [  ]Male    [  ]Female 
 
Marital Status: [  ] Single  [  ] Married      [  ] Divorced       [  ] Widowed  
 
Number of Children__________ 
 
Are you presently employed?     [  ] Yes      [  ] No 
 
Occupation:______________________________________________________ 
 
Education:  [  ] Completed High school 
  [  ] Completed Associate or Technical Degree 
  [  ] Completed College Degree (BS/BA) 
  [  ] Completed Professional Degree (i.e., MD, JD, MBA) 
  [  ] Completed Graduate Degree (i.e., MS, PhD) 
  [  ] Did not complete any of the above 
 
****************************************************************************** 
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OROFACIAL PAIN STUDY QUESTIONNAIRE 
 
 
 
 
In this questionnaire we are interested in your face or jaw pain and headaches. Please do not 
answer these questions below with regard to back pain or fibromyalgia. 
 
 
 
1. Do you currently have pain in your face or jaw?  [  ] Yes  [  ] No 
 If no, go to question 10 
 
2. If yes, when did your face/jaw pain begin?   _____________________ 
        (month / date / year) 
 
3. How did your face/jaw pain begin? 
 
 [  ]Jaw Surgery   [  ]Blow to jaw / head / neck 
 [  ]Motor vehicle accident  [  ]Dental work 
 [  ]Chewing    [  ]Tooth extraction 
 [  ]Orthodontics (braces)  [  ]Stressful Situation 
 [  ]Nothing; pain just came on 
 [  ]Other____________________________________________________ 
 
4. What is the usual severity of your face/jaw pain? (Circle the appropriate number) 
 
           |_____________________________________________________________| 
 0 1 2 3 4 5 6 7 8 9 10          
            No Pain                   Extreme Pain 
 
5. Describe the way your face/jaw pain typically feels: 
 
[  ] Throbbing  [  ] Gnawing  [  ] Splitting 
[  ] Shooting  [  ] Hot / Burning [  ] Tiring-exhausting 
[  ] Stabbing  [  ] Aching  [  ] Sickening  
[  ] Sharp  [  ] Heavy  [  ] Fearful 
[  ] Cramping  [  ] Tender  [  ] Punishing - Cruel 
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6. Where is your face or jaw pain located? Please check the following areas based on the location 
of your pain.  
 
 1. Forehead  [   ] Right side [   ] Left side  [   ] Both sides 
   
  2. Temples  [   ] Right side [   ] Left side  [   ] Both sides 
 
3. Inside the ear         [   ] Right side [   ] Left side  [   ] Both sides 
 
4. Jaw joint  [   ] Right side [   ] Left side  [   ] Both sides 
 
5.  Jaw   [   ] Right side [   ] Left side  [   ] Both sides 
 
 
 
 
7. How long does your face or jaw pain typically last? 
 
 [  ]Less than 1 minute               [  ]6-12 hours 
 [  ]1-10 minutes    [  ]13-24 hours 
 [  ]Less than 1 hour    [  ]Several days 
 [  ]1-5 hours     [  ]Constant 
 
8. Which of the following causes or aggravates your jaw or face pain? 
 
[  ]Chewing  [  ]Opening mouth wide  [  ]Hot or cold foods/drinks 
[  ]Talking  [  ]Lack of sleep   [  ]Damp or cold weather 
[  ]Yawning  [  ]Playing musical instrument [  ]Stress/emotional upset 
[  ]Laughing  [  ]Riding in car for long period [  ]Sitting for long period 
[  ]Singing  [  ]Eating certain foods  [  ]Exercise 
[  ]Other_________________________________________________________ 
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9. Which of the following relieves the pain?   
 
[  ]Exercise  [  ]Massage of the area  [  ]Warm soak/compresses 
[  ]Heat  [  ]Holding jaw in certain position [  ]Ice/cold compresses 
[  ]Sleep  [  ]Moving/manipulating jaw   [  ]Pain medication 
[  ]Time  [  ]Relaxation    [  ]Nothing helps 
[  ]Other_________________________________________________________ 
 
10. Do you have any painful teeth or other painful areas in your mouth?  
[  ]Yes  [  ]No  If Yes, please check the following based on the location of 
your pain. 
 
 
 
 
 
 
 
 
 
 
11. Are you bothered by headaches? 
 
 [  ]Yes 
 [  ]No  If no, skip to question number 12. 
  
 1)  How painful are your headaches usually? 
 |____________________________________________________________| 
 0 1 2 3 4 5 6 7 8 9 10          
            No Pain                  Extreme Pain  
 
 
 
  
 
Teeth    [   ] Yes     [   ] No 
Tongue    [   ] Yes     [   ] No 
Gums   [   ] Yes     [   ] No 
Roof of mouth  [   ] Yes     [   ] No 
Cheek    [   ] Yes     [   ] No 
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2)  Do you have headaches as often as once per week? 
  [   ]Yes    [   ]No 
 
 3) How long do your headaches last?  
  [   ] less than 1 hour  [   ] greater than 1 hour but less than 24 hrs 
  [   ] greater than 24 hours [   ] constant headache 
 
4)  Is there any nausea or vomiting associated with your headaches? 
  [   ]Yes    [   ]No 
 
 5)  Are there vision changes associated with your headaches? 
  [   ]Yes    [   ]No 
  
 6)  Are you disabled (unable to function normally) by your headaches? 
  [   ]Yes    [   ]No 
 
7)  Has a doctor diagnosed you with 
 [   ] Migraine   [   ] tension type headache 
 [   ] Other __________________________________ 
 
12. Are you aware of your jaw making sounds? 
 
 [  ]Yes    [  ]No 
    
   If yes, please answer the following questions, if no, go to question #13. 
 
 Which side? [  ]Right [  ]Left  [  ]Both sides 
  
 Describe the nature of the sound: 
 [  ]Clicking [  ]Grating [  ]Popping [  ]Cracking 
 [  ]Other___________________________________________________ 
 
 When do you notice the sounds? 
 [  ]Early opening  [  ]Moving jaw to the side 
 [  ]Middle opening  [  ]Chewing 
 [  ]Wide opening  [  ]While closing 
 
 Is the sound always present? 
  [  ]Yes    [  ]No 
 
 Do you feel that the sounds are related to your jaw or face pain or headaches: 
  [  ]Yes    [  ]No 
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13 Has your jaw ever locked open? 
 
 [  ]Yes     [  ]Right side  [  ]Both sides 
 [  ]No     [  ]Left side 
 
Date of first occurrence________________________     (month / date/ year) 
 
14 Has your jaw ever locked closed or partially closed? 
 
 [  ]Yes     [  ]Right side  [  ]Both sides 
 [  ]No     [  ]Left side 
 
Date of first occurrence__________________________(month / date/ year) 
 
15  How many times has your jaw locked open or closed during the past year? 
[  ] none   # of times___________ 
 
16 Do you have pain when your jaw locks open or closed? 
 
 [  ]Yes    [  ]No 
 
17 Have you noticed any other oral habits or practices that aggravate or cause your face /jaw 
pain or headaches? 
 
[  ]Clenching the teeth               [  ]Grinding the teeth 
[  ]Chewing ice     [  ]Chewing finger nails 
[  ]Chewing pencil/paper clips   [  ]Chewing cheek/lips 
[  ]Chewing gum      [  ]Playing wind instruments/violin 
[  ]Holding phone between ear and shoulders [  ]Other_________________________ 
 
18. For each of the beverages listed below, write in the average number that you will drink 
each day: 
 
Caffeinated coffee    _____cups/day 
Caffeinated soft drink  _____cans/bottles/day 
Caffeinated Tea _____cups/day 
Decaffeinated beverages including juices and milk _____cups/day 
Alcoholic beverages ____ drinks/cans/day 
Water ________ cups/day 
 
 
 
 
 
19.  Do you use tobacco?    [  ] no   [  ] yes 
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20. Are you receiving or applying for disability? [  ]  no  [  ]  yes                                          
            For :           [  ] Face or jaw pain 
   [  ] Fibromyalgia 
   [  ] Chronic lower back pain 
   [  ] Depression / Anxiety 
   [  ] Other, please specify _________________ 
 
21. Are you taking or supposed to be taking and medicine, drugs or pills of any kind? 
 Taking     Supposed to be taking 
 _______________________  ____________________ 
 _______________________  ____________________ 
 _______________________  ____________________ 
 _______________________  ____________________ 
 _______________________  ____________________ 
 _______________________  ____________________ 
 _______________________  ____________________ 
 _______________________  ____________________ 
 _______________________  ____________________ 
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University of Kentucky Orofacial Pain Questionnaire
General Medical History 
 
Please check the box for any condition which you have had in the past or have now. 
 
(1) Cardiovascular 
? Congestive Heart Failure 
? Heart Attack 
? Angina Pectoris or Chest Pain 
? High Blood Pressure 
? Heart Murmur 
? Mitral Valve Prolapse 
? Rheumatic Fever 
? Congenital Heart Defect 
? Artificial (Prosthetic) Heart 
Valve 
? Arrhythmias 
? Heart Pacemaker or Defibrillator 
? Coronary By-Pass 
? Coronary Angioplasty 
? Heart Transplant 
? Aneurysm 
? Other Heart Problems 
 
(2) Hematologic 
? Blood Transfusion 
? Anemia 
? Hemophilia 
? Leukemia 
? Sickle Cell Anemia 
? Tendency to Bleed Longer Than 
Normal 
 
(3) Neurologic 
? Vision Problems 
? Glaucoma 
? Earache, Ringing in Ears 
? Hearing Loss 
? Severe Headaches 
? Fainting or Dizzy Spells 
? Stroke 
? Epilepsy, Seizures or 
Convulsions 
? Psychiatric Treatment 
? Panic Attacks 
? Phobias 
 
 
 
(4) Gastrointestinal 
? Stomach/Intestinal Ulcers 
? Colitis 
? Irritable Bowel Syndrome 
? Persistent Diarrhea 
? Hepatitis 
? Liver Disease 
? Yellow Jaundice 
? Cirrhosis 
? Eating Disorder 
? Gastric Acid Reflux 
 
(5) Pulmonary 
? Hay Fever 
? Sinus Trouble 
? Allergies or Hives 
? Asthma 
? Chronic Cough 
? Emphysema 
? Chronic Bronchitis 
? Tuberculosis (TB) 
? Breathing Difficulties 
? Sarcoidosis 
 
(6) Dermal / 
Musculoskeletal 
? Allergy to Latex (Rubber) 
? Skin Rash 
? Dark Mole(s) (Recent changes in 
appearance) 
? Osteoarthritis 
? Rheumatoid Arthritis 
? Systemic Lupus 
? Artificial (Prosthetic ) Joint 
? Fibromyalgia 
? Chronic Fatigue Syndrome 
? Scleroderma 
? Sjogren’s Syndrome 
? CRPS I (RSD) 
? CRPS II (Causalgia) 
 
 
                   8 
(7) Endocrine 
? Diabetes 
? Thyroid Disease 
? Taking Cortisone or Other 
Steroids 
? Hormone Replacement Therapy 
 
(8) Genitourinary 
? Urinate Frequently 
? Kidney, Bladder Problem 
? Dialysis 
? Kidney Transplant 
? Sexually Transmitted Disease 
(Syphilis, Gonorrhea, Chlamydia 
or Genital Herpes) 
? HIV Positive 
? Multiple Sexual Partners 
? Interstitial Cystitis 
? Endometriosis 
 
(9) Other Conditions 
? Anxiety Disorder 
? Depression 
? Frequent Sore Throats 
? Enlarged Lymph Node or 
“Gland” 
? Use Tobacco 
? Use Alcohol 
? Use Injectable Drugs 
? Drug or Alcohol Addiction 
(Recovery or Current) 
? Tumor or Cancer 
? Radiation Therapy 
? Chemotherapy 
? Sleep Apnea 
? Snoring 
? Disease, Problem or Condition 
not listed 
If yes, list 
_____________________________
_____________________________
_____________________________
_____________________________
_____________________________
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Appendix 2: Orofacial Pain Examination Form 
 
 
ID: ___________________       Date:___________ 
 
Orofacial Pain Examination 
 
Cranial Nerve Examination: 
 
(II) Gross Vision,     WNL:_________________________________________ 
(III) (III, IV, VI) Extraocular Muscles WNL:_________________________________________ 
    Pupils (Equality, Reaction, Accommodation) WNL:____________________________________ 
(V)  Sensory (V1, V2, V3)  WNL________________________________________________ 
(V) Motor  (Function, Symmetry)  WNL:__________________________________________ 
(VII) Motor (Facial Muscles)  WNL:__________________________________________ 
(VIII) Gross Hearing  WNL:______________________________________________________ 
     EAC and TM         WNL:_____________________________________________________ 
(IX, X) Gag Reflex       WNL:______________________________________________________ 
(XI) Shoulder Shrug/Lateral Head Movement WNL:____________________________________ 
(XII) Tongue Protrusion WNL:______________________________________________________ 
 
Balance/Coordination: 
WNL :_________________________________________________________________________ 
   (Tests: finger to nose; alternate hands; toe to heel walking) 
 
Cervical Range of Movement: 
               Pain                    Restriction  
      Flexion / Extension          None        Ex           Flex                 None        Ex            Flex 
      Rotation (70 degrees)       None        Right        Left                None        Right        Left 
      Lateral Tilt (60 degrees)   None        Right        Left                None        Right        Left 
 
General Comments:________________________________________________________________ 
________________________________________________________________________________
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Muscle and Joint Palpation Examination: 
     Codes: 0= no pain, 1= tenderness, 2= pain, 3= pain with withdrawal, T= trigger point,  
                      (if there is pain referral, draw an arrow to depict direction and location) 
   Right  Left 
Temporalis 
     Anterior  _____  _____ 
     Middle  _____  _____ 
     Posterior  _____  _____ 
Masseter 
     Superior  _____  _____ 
     Inferior  _____  _____ 
SCM   _____  _____ 
Occipital  _____  _____ 
Trapezius  _____  _____ 
Paracervical  _____  _____ 
Cervical Spine             _____  
TMJ 
     Lateral Capsule _____  _____ 
     EAC   _____  _____ 
     Splenius Capitis _____  _____   
 
                  Pain on Mandibular Function:     Provocation Tests: 
 
        pain with opening:     [ ] No  [ ] Right  [ ]  Left                     Clenching on separator: 
      pain with clenching:     [ ] No  [ ] Right  [ ]  Left   bilaterally:  [ ] No  [ ] Right  [ ]  Left 
with right lat movement:     [ ] No  [ ] Right  [ ]  Left           right:  [ ] No  [ ] Right  [ ]  Left 
with left lat movement:       [ ] No  [ ] Right  [ ]  Left             left:  [ ] No  [ ] Right  [ ]  Left 
                           
                                              Resisted Movements: 
          resisted protrusion: [ ] No  [ ] Right  [ ]  Left 
        resisted right lateral: [ ] No  [ ] Right  [ ]  Left 
          resisted left lateral: [ ] No  [ ] Right  [ ]  Left 
Range of Mandibular Movement:          
          Manual loading of TMJs 
                       Closed       [ ] no pain  [ ] Right  [ ] Left 
 
     10mm                                 10mm      
R ___mm                          L ___mm               
                 Max protrusive movement  ___mm   
  Draw 
deflection           Max comfortable opening ____mm   
      or                      Max opening by patient ____mm 
deviations           Max assisted opening ____mm 
 
    or 
 
straight Opened     End Feel:  [ ] Soft   [ ] Hard  [ ] Not Indicated 
                                               89
Intracapsular Interferences:               
 
               opening click              closing click 
 
        Right TMJ    [ ] No   [ ] Yes at ____mm   [ ] No   [ ] Yes at ____mm 
        Left TMJ      [ ] No   [ ] Yes at ____mm   [ ] No   [ ] Yes at ____mm 
 
Clicking during: 
 Right lateral movements:  [ ] No  [ ] Right  [ ] Left  
 Left lateral movements     [ ] No  [ ] Right  [ ] Left  
 
The click is:        The click is eliminated by protrusion 
 [ ] very repeatable     [ ] No  [ ] Yes at ____mm of protrusion 
 [ ] not very repeatable 
 [ ] there is no click      Crepitus:   [ ] No   [ ] Right   [ ] Left 
 
Intraoral Examination: 
Intraoral Muscle Palpation: 
      Right               Left 
  Temporal Tendon  _____  _____ 
  Medial Pterygoid  _____  _____ 
  Anterior Digastric  _____  _____ 
 
Soft Tissue:  [ ] WNL _______________________________________________________________ 
                     ______________________________________________________________________ 
 
Periodontal Health  [ ] WNL, _________________________________________________________ 
                    ______________________________________________________________________ 
 
General Description of Dentition:_____________________________________________________ 
  ______________________________________________________________________ 
  ______________________________________________________________________ 
 
Tooth Wear:  Anterior teeth   [ ]  none   [ ]  enamel only   [ ]  enamel and dentin 
           Posterior teeth  [ ]  none   [ ]  enamel only   [ ]  enamel and dentin 
 
Occlusal Examination: 
Profile:  [ ] Orthognathic    [ ]  Retrognathic    [ ] Prognathic 
Anterior tooth  relationship:  [ ] Class I   [ ]  Class II, Div 1  [ ] Class II, Div 2    [ ]  Class III   [ ] Open bite 
Posterior tooth  relationship: [ ] Class I  [ ]  Class II  [ ] Class III   [ ] Open bite (right, left or both) 
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Circle the areas of occlusal contacts; cross missing teeth 
 
Intercuspal Position     Non-Working   
 
M3 M2 M1 P2 P1 C I2 I1 I1 I2 C P1 P2 M1 M2 M3  M3 M2 M1 P2 P1 C I2 I1 I1 I2 C P1 P2 M1 M2 M3 
 
 
R    none        L  R   none  L 
 
M3 M2 M1 P2 P1 C I2 I1 I1 I2 C P1 P2 M1 M2 M3  M3 M2 M1 P2 P1 C I2 I1 I1 I2 C P1 P2 M1 M2 M3 
 
 
 
Protrusive      Working Contacts  
 
M3 M2 M1 P2 P1 C I2 I1 I1 I2 C P1 P2 M1 M2 M3  M3 M2 M1 P2 P1 C I2 I1 I1 I2 C P1 P2 M1 M2 M3 
 
 
R    none        L  R   none  L 
 
M3 M2 M1 P2 P1 C I2 I1 I1 I2 C P1 P2 M1 M2 M3  M3 M2 M1 P2 P1 C I2 I1 I1 I2 C P1 P2 M1 M2 M3 
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